| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 7774 from our risk checks.
Japan Tissue Engineering Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥520.00 |
| 52 Week High | JP¥811.00 |
| 52 Week Low | JP¥472.00 |
| Beta | 0 |
| 11 Month Change | -10.19% |
| 3 Month Change | -24.42% |
| 1 Year Change | -5.63% |
| 33 Year Change | -25.93% |
| 5 Year Change | -40.37% |
| Change since IPO | 31.98% |
Recent News & Updates
Shareholder Returns
| 7774 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 0.4% | 7.1% | 2.7% |
| 1Y | -5.6% | 16.5% | 10.1% |
Return vs Industry: 7774 underperformed the JP Biotechs industry which returned 16.5% over the past year.
Return vs Market: 7774 underperformed the JP Market which returned 10.1% over the past year.
Price Volatility
| 7774 volatility | |
|---|---|
| 7774 Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 13.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in JP Market | 10.4% |
| 10% least volatile stocks in JP Market | 3.5% |
Stable Share Price: 7774's share price has been volatile over the past 3 months.
Volatility Over Time: 7774's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 211 | Ken-Ichiro Hata | www.jpte.co.jp |
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment.
Japan Tissue Engineering Co., Ltd. Fundamentals Summary
| 7774 fundamental statistics | |
|---|---|
| Market cap | JP¥21.12b |
| Earnings (TTM) | -JP¥81.97m |
| Revenue (TTM) | JP¥2.29b |
9.2x
P/S Ratio-257.6x
P/E RatioIs 7774 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7774 income statement (TTM) | |
|---|---|
| Revenue | JP¥2.29b |
| Cost of Revenue | JP¥816.44m |
| Gross Profit | JP¥1.48b |
| Other Expenses | JP¥1.56b |
| Earnings | -JP¥81.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
| Earnings per share (EPS) | -2.02 |
| Gross Margin | 64.41% |
| Net Profit Margin | -3.57% |
| Debt/Equity Ratio | 0% |
How did 7774 perform over the long term?
See historical performance and comparison